Skip to main content
. Author manuscript; available in PMC: 2021 Mar 15.
Published in final edited form as: J Immunol. 2020 Feb 14;204(6):1689–1696. doi: 10.4049/jimmunol.1900889

Figure 3: Tetramer analysis.

Figure 3:

Mamu-A1*001 MHC-peptide tetramers were generated and tested for binding to PBMC from SIV-infected animals. (A) A representative sequential gating strategy for the flow cytometry data is shown. (B) Tetramer binding to PBMC from three animals was tested; shown are the ELISPOT responses to each peptide (STPESANLG, STPESANLGE, and TPESANLG are abbreviated as SG9, SE10, and TE9 respectively), and the percentage of CD8 T cells that were tetramer-positive.